Glenmark Pharmaceuticals Limited (BOM: 532296)
India
· Delayed Price · Currency is INR 1,641.55
+19.15 (1.18%)
At close: Jan 7, 2025
Glenmark Pharmaceuticals Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jan '25 Jan 6, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Market Capitalization | 449,610 | 270,463 | 131,124 | 124,718 | 131,124 | 58,084 | Upgrade
|
| Market Cap Growth | 95.63% | 106.27% | 5.14% | -4.88% | 125.75% | -68.19% | Upgrade
|
| Enterprise Value | 449,215 | 315,126 | 164,781 | 152,778 | 150,427 | 81,820 | Upgrade
|
| Last Close Price | 1592.90 | 954.77 | 462.32 | 436.82 | 456.74 | 201.57 | Upgrade
|
| PE Ratio | - | - | 44.11 | 13.24 | 13.52 | 7.49 | Upgrade
|
| PS Ratio | 3.61 | 2.14 | 1.12 | 1.01 | 1.20 | 0.55 | Upgrade
|
| PB Ratio | 5.59 | 3.45 | 1.33 | 1.32 | 1.86 | 0.96 | Upgrade
|
| P/TBV Ratio | 6.66 | 4.15 | 1.86 | 1.83 | 2.77 | 1.49 | Upgrade
|
| P/FCF Ratio | - | - | 743.79 | 39.15 | 36.79 | 12.60 | Upgrade
|
| P/OCF Ratio | - | - | 20.97 | 11.25 | 11.59 | 4.17 | Upgrade
|
| EV/Sales Ratio | 3.43 | 2.49 | 1.41 | 1.24 | 1.37 | 0.77 | Upgrade
|
| EV/EBITDA Ratio | 20.52 | 17.22 | 11.53 | 7.99 | 7.73 | 5.49 | Upgrade
|
| EV/EBIT Ratio | 25.21 | 21.80 | 14.48 | 8.30 | 8.77 | 6.30 | Upgrade
|
| EV/FCF Ratio | -21.63 | - | 934.71 | 47.96 | 42.20 | 17.75 | Upgrade
|
| Debt / Equity Ratio | 0.21 | 0.16 | 0.47 | 0.42 | 0.71 | 0.85 | Upgrade
|
| Debt / EBITDA Ratio | 0.81 | 0.64 | 3.03 | 1.98 | 2.45 | 3.30 | Upgrade
|
| Debt / FCF Ratio | - | - | 261.38 | 12.44 | 13.99 | 11.25 | Upgrade
|
| Asset Turnover | 0.74 | 0.75 | 0.64 | 0.75 | 0.72 | 0.76 | Upgrade
|
| Inventory Turnover | 1.59 | 1.87 | 1.81 | 1.90 | 1.74 | 1.75 | Upgrade
|
| Quick Ratio | 0.76 | 0.75 | 1.06 | 1.08 | 1.00 | 0.97 | Upgrade
|
| Current Ratio | 1.46 | 1.28 | 2.10 | 1.77 | 1.75 | 1.65 | Upgrade
|
| Return on Equity (ROE) | -10.93% | -20.70% | -0.93% | 12.04% | 14.77% | 13.29% | Upgrade
|
| Return on Assets (ROA) | 6.32% | 5.36% | 3.90% | 7.04% | 7.08% | 5.80% | Upgrade
|
| Return on Capital (ROIC) | 8.86% | 7.68% | 5.11% | 9.04% | 9.20% | 7.62% | Upgrade
|
| Earnings Yield | -1.95% | -5.55% | 2.27% | 7.55% | 7.40% | 13.36% | Upgrade
|
| FCF Yield | -4.40% | -4.30% | 0.13% | 2.55% | 2.72% | 7.94% | Upgrade
|
| Dividend Yield | 0.15% | 0.26% | 0.54% | 0.57% | 0.55% | 1.24% | Upgrade
|
| Payout Ratio | 0.00% | - | 23.68% | 9.84% | 7.26% | 8.83% | Upgrade
|
| Buyback Yield / Dilution | -0.03% | -0.00% | - | - | - | 0.00% | Upgrade
|
| Total Shareholder Return | 0.12% | 0.26% | 0.54% | 0.57% | 0.55% | 1.24% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.